Evotec (EVT.DE) traded up 2.64 % during a 24 hours period ending at 10:52 AM Central Europe on Wednesday 28th. One Evotec stock can currently be bought for about EUR 2.93 on popular exchanges. Current supply of Evotec stocks is 177.7 mn. Evotec has a current market capitalization of EUR 511 mn and approximately EUR 1.6 mn worth of Evotec was traded on exchanges in the last 24 hours. Since last month end, Evotec has traded 0.56 % up. Simple moving average of last 200 days is at EUR 4.42. The highest price of past 52 weeks was recorded at EUR 7.17 on 11/03/2025. 52 weeks low was at EUR 2.41 on 10/13/2026.

Summary of the latest news for Evotec

Five years ago, investors who purchased shares of EVOTEC SE on the German exchange were able to hold a significant number of shares, but the company’s stock price has fallen sharply. The stock’s value on the day it first traded was roughly forty‑one euros, while the current closing price is less than three euros, reflecting a steep decline. Over the period, the company’s market capitalization has decreased to just under five hundred million euros. The company first entered the market in late 1999, with an opening price of twelve euros. These developments indicate a persistent downturn in the company’s share performance, with the decline persisting over several years.

Here is how related stocks have performed in the past 24 hours:

  • First Sensor (SIS.DE) traded down -1.89 % and now trades at EUR 52. First Sensor has a market capitalisation of EUR 527.3 mn.

  • Mensch Und Maschine Software (MUM.DE) traded down -0.59 % and now trades at EUR 33.75. Mensch Und Maschine Software has a market capitalisation of EUR 554.9 mn. Mensch Und Maschine Software has a current price to earnings ratio of 17.2. MENSCH UND MASCHINE SOFTWARE announced a strategic partnership with a university research centre to advance the ethical integration of conversational AI in social services. The collaboration focuses on studying how language technology can support caring interactions without replacing human empathy. Researchers will examine the social implications of automated communication tools, particularly in sensitive professional settings, and develop guidelines for responsible deployment. The initiative aligns with broader efforts to understand the societal effects of generative AI and aims to inform policy and practice in the industry.

  • Hypoport (HYQ.DE) traded down -0.06 % and now trades at EUR 81.3. Hypoport has a market capitalisation of EUR 538.2 mn. Hypoport has a current price to earnings ratio of 19.01. German equity markets opened with cautious sentiment, as investors weighed upcoming U.S. tech earnings and central‑bank policy moves. The DAX edged slightly higher, while the Euro‑zone benchmark slipped modestly. Among the SDAX constituents, Hypoport continued to lift the index with a small gain, whereas other names such as Suss Microtec and Beiersdorf experienced declines following their latest quarterly reports. In the broader market, the performance of key German groups reflected a mix of resilient earnings and cautious outlooks, with some firms adjusting profit forecasts amid shifting economic conditions. The day’s trade highlighted the market’s sensitivity to macro‑economic signals and company‑specific developments.

  • Patrizia (PAT.DE) traded down -0.16 % and now trades at EUR 6.3. Current market capitalisation for Patrizia is EUR 545.5 mn. Current price/earnings ratio for Patrizia is 19.09.

  • Innoscripta (1INN.DE) traded down -2.87 % and now trades at EUR 50.7. Innoscripta has a market capitalisation of EUR 522 mn. Current price/earnings ratio for Innoscripta is 17.03. German growth company INNOSCRIPTA SE experienced a sharp decline in its share price following a regulatory inspection that prompted a significant drop. Management has expressed confidence that the company is addressing the issues raised, and early indications suggest that the market may soon reassess the company’s valuation. Analysts note that the recent downturn has highlighted potential undervaluation, and some observers anticipate a reversal as the company stabilises its operations and implements corrective measures. The situation remains under close scrutiny, with market participants monitoring both the company’s response and broader sector sentiment for further developments.

About Evotec

Evotec SE is a pharmaceutical company specializing in drug discovery solutions in various therapeutic areas including neuroscience, diabetes, pain and inflammation, oncology, infectious diseases, respiratory, and fibrosis. The company serves pharmaceutical and biotechnology companies worldwide, striving to develop innovative therapies to address unmet medical needs.